Danaher Stock Falls After Q2 Earnings - Here's Why

Danaher Corp (NYSE: DHR) has logged Q2 FY23 adjusted EPS of $2.05, down from $2.76 a year ago, surpassing the consensus of $2.01.

Sales decreased 7.5% Y/Y to $7.16 billion, beating the consensus of $7.11 billion, with a 7% non-GAAP core revenue decrease, due to lower COVID-19 revenue and 2% non-GAAP base business core revenue growth

Operating cash flow for the second quarter was $1.9 billion, and non-GAAP free cash flow was $1.6 billion.

Rainer Blair, President & CEO, stated, "We are pleased with our second quarter results which met our expectations, despite a more dynamic operating environment. Our team's consistent execution, paired with better-than-expected performance in our Life Science and Diagnostics businesses, including stronger respiratory testing revenue, helped offset softer demand in bioprocessing."

The gross margin remained almost unchanged at 61%.

Guidance: For Q3, Danaher anticipates non-GAAP base business core revenue will be down low-single digits year-over-year

For FY23, the company anticipates non-GAAP base business core revenue growth will be up low-single digits year-over-year, compared to high-single digits earlier.

Price Action: DHR shares are down 4.64% at $246.01 during the premarket session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!